AbsEn.i
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « predict »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
precursors < predict < predictable  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 29.
[0-20] [0 - 20][0 - 29][20-28][20-40]
Ident.Authors (with country if any)Title
000065 (2012) César Faillace [Brésil] ; Jozélio Freire De Carvalho [Brésil]Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis
000083 (2012) Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon]The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
000134 (2013) F. Behrens [Allemagne] ; M. Köhm [Allemagne]Personalisierte Medizin bei Zytokin-gerichteten Therapien
000147 (2010) Tamotsu Kamishima [Japon] ; Kazuhide Tanimura [Japon] ; Masato Shimizu [Japon] ; Megumi Matsuhashi [Japon] ; Jun Fukae [Japon] ; Yujiro Kon [Royaume-Uni] ; Hiromi Hagiwara [Japon] ; Akihiro Narita [Japon] ; Yuko Aoki [Japon] ; Naoki Kosaka [Japon] ; Tatsuya Atsumi [Japon] ; Hiroki Shirato [Japon] ; Satoshi Terae [Japon]Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger
000154 (2011) Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon]Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI
000210 (2013) K K Machavaram [Royaume-Uni] ; L M Almond [Royaume-Uni] ; A. Rostami-Hodjegan [Royaume-Uni] ; I. Gardner [Royaume-Uni] ; M. Jamei [Royaume-Uni] ; S. Tay [États-Unis] ; S. Wong [États-Unis] ; A. Joshi [États-Unis] ; J R Kenny [États-Unis]A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL‐6
000284 (2012) Usama Elewa [Espagne] ; Maria Dolores Sanchez-Ni O [Espagne] ; Catalina Martin-Cleary [Espagne] ; Beatriz Fernandez-Fernandez [Espagne] ; Jesus Egido [Espagne] ; Alberto Ortiz [Espagne]Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
000337 (2011) Sylvie Fabre [France]Approches pharmacologiques en immuno-rhumatologie
000455 (2012) Yukihiko Saeki [Japon] ; Eriko Kudo-Tanaka [Japon] ; Shiro Ohshima [Japon] ; Masato Matsushita [Japon] ; So-Ichiro Tsuji [Japon] ; Yu-Ichi Maeda [Japon] ; Maiko Yoshimura [Japon] ; Akane Watanabe [Japon] ; Yoshinori Katada [Japon] ; Yoshinori Harada [Japon] ; Kenji Ichikawa [Japon] ; Yasuo Suenaga [Japon] ; Yusuke Ohta [Japon] ; Shigeto Tohma [Japon]Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA)
000528 (2013) I. Guseva ; N. Soroka [Russie] ; A. Devyataykina ; G. Lukina ; E. Aleksandrova ; A. Novikov ; S. Glukhova ; D. Trofimov [Russie] ; E. Nasonov [Russie]AB0538 TNFAIP3 RS675520 variant may predict response to rituximab treatment in rheumatoid arthritis
000791 (2013) L. Xie ; M. C. Genovese [États-Unis] ; B. Zhu ; E. Edson-Heredia ; S. BanerjeeSAT0137 Early Clinical Improvements (Week 4) Predict Subsequent Clinical Response with Ixekizumab in Rheumatoid Arthritis Patients with Inadequate Response to tnf Inhibitors
000803 (2012) Sharon Cohen [Israël] ; Ilan Bruchim [Israël] ; Dror Graiver [Israël] ; Zoharia Evron [Israël] ; Varda Oron-Karni [Israël] ; Metsada Pasmanik-Chor [Israël] ; Ram Eitan [Israël] ; Joelle Bernheim [Israël] ; Hanoch Levavi [Israël] ; Ami Fishman [Israël] ; Eliezer Flescher [Israël]Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2
000852 (2013) T. Kojima ; K. Funahashi ; N. Takahashi ; D. Kato ; H. Matsubara ; Y. Hattori ; Y. Yabe [Japon] ; N. IshiguroTHU0124 Importance of monitoring of C-reactive protein level to predict achievement of better clinical outcome during treatment with tocilizumab in patients with rheumatoid arthritis
000906 (2013) N. Nishina [Japon] ; J. Kikuchi [Japon] ; M. Hashizume [Japon] ; K. Yoshimoto [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon]FRI0001 Baseline soluble interleukin-6 receptor levels predict the clinical effectiveness of tocilizumab in patients with rheumatoid arthritis
000A04 (2013) A. Filer [Royaume-Uni] ; M. Z. Cader [Royaume-Uni] ; A. Abhishek [Royaume-Uni] ; G. Allen [Royaume-Uni] ; C. Buckley [Royaume-Uni] ; P. De Pablo [Royaume-Uni] ; K. Raza [Royaume-Uni]OP0052 Use of ultrasound to predict persistence in patients with very early synovitis
000A09 (2013) B. Missler-Karger [Allemagne] ; M. Leu ; M. A. Raboisson ; B. Pilstrom [Suède]FRI0219 Disease severity, no steroid use and type ii diabetes predict response to anakinra (kineret®) in patients with rheumatoid arthritis
000A54 (2011) Homam Alkaied [États-Unis] ; Kassem Harris [États-Unis] ; Dany Elsayegh [États-Unis] ; Inga Khachaturova [États-Unis] ; Michael Awasum [États-Unis] ; Seema Varma [États-Unis]Does Kaposi’s sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?
000C43 (2013) G. Westhoff [Allemagne] ; J. Callhoff [Allemagne] ; E. Edelmann [Allemagne] ; A. Zink [Allemagne]FRI0130 Fatigue, feeling blue and obesity, but not disease activity, predict whether patients with early inflammatory arthritis are able to walk considerable distances
000C95 (2011) Kamal Esalatmanesh [Iran] ; Raika Jamali [Iran] ; Arsia Jamali [Iran] ; Bardia Jamali [Iran] ; Mohammadreza Nikbakht [Iran]Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
000E34 (2011) Batool Zamani [Iran] ; Raika Jamali [Iran] ; Arsia Jamali [Iran]Serum adenosine deaminase may predict disease activity in rheumatoid arthritis
000F82 (2009) Paula I. Burgos ; Maria I. Danila [États-Unis] ; James M. Kelley [États-Unis] ; Laura B. Hughes [États-Unis] ; S. Louis Bridges [États-Unis]Understanding personalized medicine in rheumatoid arthritis: a clinician’s guide to the future

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "predict" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "predict" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    predict
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021